Effects of octreotide therapy in progressive head and neck paragangliomas: Case series

Autor:	Nicolette van Duinen, Jeroen C. Jansen, Eleonora P M Corssmit, Leonie T. van Hulsteijn, Agatha A. van der Klaauw, Berit M. Verbist, Jan W. A. Smit
Rok vydání:	2013
Předmět:	medicine.medical_specialty business.industry Somatostatin receptor Urology Octreotide Signs and symptoms Surgery Somatostatin Otorhinolaryngology medicine Tumor growth business Head and neck Intramuscular injection Somatostatin analog medicine.drug
Zdroj:	Head & Neck. 35:E391-E396
ISSN:	1043-3074
DOI:	10.1002/hed.23348
Popis:	BACKGROUND: Octreotide, a somatostatin analog, may be beneficial in the treatment of head and neck paragangliomas (HNPGLs). METHODS: We conducted a nonblinded, prospective intervention study. During 1 year, patients received a monthly intramuscular injection of 30 mg octreotide. Pretreatment and posttreatment tumor volumes were assessed by MRI, urinary catecholamine secretion was measured, and HNPGL-related signs and symptoms were recorded. RESULTS: In 1 of 4 included patients with HNPGL, a stabilization of tumor growth was observed after octreotide therapy. In 1 patient, octreotide therapy was discontinued before the end of the study because of potential side effects. No improvements in HNPGL-related signs and symptoms were observed. CONCLUSION: In 1 of 4 patients, HNPGL tumor growth velocity was reduced after octreotide therapy. Research assessing the effects of somatostatin analogues targeting different somatostatin receptor subtypes or combined with other therapies may offer new possibilities for the treatment of HNPGLs. (c) 2013 Wiley Periodicals, Inc. Head Neck 35: E391-E396, 2013.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::abf48381c6cd6a52b03f9072c5163207 https://doi.org/10.1002/hed.23348 Zobrazit plný text záznamu Plný text